New eczema drug GS101 takes on dupixent in major trial
Disease control
Not yet recruiting
This phase 3 trial compares a new injectable drug, GS101, to the established treatment Dupixent for adults with moderate-to-severe atopic dermatitis (eczema). About 572 participants will receive either GS101 or Dupixent every other week for a year. The main goal is to see if GS10…
Phase: PHASE3 • Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC